IPSIndian Journal of Pharmacology
Home  IPS  Feedback Subscribe Top cited articles Login 
Users Online : 322 
Small font sizeDefault font sizeIncrease font size
Navigate Here
  Search
 
  Next article
  Previous article 
  Table of Contents
  
Resource Links
   Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
   Article in PDF (233 KB)
   Citation Manager
   Access Statistics
   Reader Comments
   Email Alert *
   Add to My List *
* Registration required (free)

 
In This Article
   References

 Article Access Statistics
    Viewed1914    
    Printed74    
    Emailed0    
    PDF Downloaded149    
    Comments [Add]    

Recommend this journal

 


 
LETTER TO EDITOR
Year : 2010  |  Volume : 42  |  Issue : 3  |  Page : 197
 

Irbesartan in experimental diabetic nephropathy


1 Department of Pharmacology, Adesh Institute of Medical Sciences and Research, Bathinda - 141 109, Punjab, India
2 Department of Biochemistry, Adesh Institute of Medical Sciences and Research, Bathinda - 141 109, Punjab, India
3 Department of Pharmacology, Government Medical College, Amritsar - 143 001, Punjab, India

Date of Web Publication28-Jul-2010

Correspondence Address:
Rajiv Mahajan
Department of Pharmacology, Adesh Institute of Medical Sciences and Research, Bathinda - 141 109, Punjab
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0253-7613.66849

Rights and Permissions



How to cite this article:
Mahajan R, Gupta K, Singh NR. Irbesartan in experimental diabetic nephropathy. Indian J Pharmacol 2010;42:197

How to cite this URL:
Mahajan R, Gupta K, Singh NR. Irbesartan in experimental diabetic nephropathy. Indian J Pharmacol [serial online] 2010 [cited 2020 Sep 25];42:197. Available from: http://www.ijp-online.com/text.asp?2010/42/3/197/66849


Sir,

We read the article "Biochemical effects of irbesartan in experimental diabetic nephropathy" published in IJP [1] with great enthusiasm. We have the following observations to make regarding this article:

  1. This study discussed the beneficial effects of irbesartan in counteracting some biochemical or functional changes of diabetic nephropathy (DN) in experimental animals, while irbesartan has already been approved for use in DN in humans. [2] The relevance of this study is, therefore, debatable.
  2. In our opinion, instead of insulin, a drug chosen from the same group or an angiotensin-converting enzyme (ACE) inhibitor having an established role in DN would have been better.
  3. In methods, while discussing groups, animals pre-treated with irbesartan and insulin have been referred to as group III and group IV, respectively. However, in all three tables, animals pre-treated with insulin have been referred to as group III and animals pre-treated with irbesartan have been referred to as group IV. Now, which one of these statements is true and figures mentioned in tables belong to which group actually?
  4. In results, it is mentioned that insulin pre-treatment completely prevented proteinuria, but proteinuria actually increased with insulin pre-treatment (group III) as compared to diabetic rats (group IV) by 50-60 times. Which one of the statements is true?
  5. It is clear that creatinine clearance was 1.1 ± 0.18 ml/min at 0 weeks in normal rats (group I), which suddenly increased to 20.8 ± 0.84 ml/min at 4 weeks. It remained static, but again had a sudden fall from 21.3 ± 0.86 ml/min to 1.2 ± 0.06 ml/min within a period of 4 weeks. Is there any possible explanation why this happened in normal rats?


 
  References Top

1.Vaishya R, Singh J, Lal H. Biochemical effects of irbesartan in experimental diabetic nephropathy. Indian J Pharmacol 2009;41:252-4.  Back to cited text no. 1  [PUBMED]  Medknow Journal  
2.Jackson EK. Renin and angiotensin. In: Brunton LL, Lazo JS, Parker KL, editors. Goodman and Gilman's The pharmacological basis of therapeutics. 11 th ed. New York: McGraw-Hill; 2006. p. 813.  Back to cited text no. 2      




 

Top
Print this article  Email this article

    

Site Map | Home | Contact Us | Feedback | Copyright and Disclaimer
Online since 20th July '04
Published by Wolters Kluwer - Medknow